The effect of antihypertensive treatment on arterial stiffness and serum concentration of selected matrix metalloproteinases

Abstract

IntroductionThe aim of the study was to assess the arterial stiffness and serum levels of selected metalloproteinases (MMPs) in hypertensive patients and their changes following antihypertensive therapy.Material and methodsThe study group consisted of 95 patients with essential arterial hypertension (HT) stage 1 or 2 (mean age: 53.1 ±13.0 years). The control group consisted of 31 normotensives of the same age range. Hypertension patients were randomized to one of the following monotherapies for 6 months: quinapril, losartan, amlodipine, hydrochlorothiazide or bisoprolol. Carotid-femoral pulse wave velocity (PWV) was measured using a Complior device. Serum concentrations of MMPs (proMMP-1, MMP-2, MMP-3, MMP-9) and plasma concentration of tissue inhibitor of MMPs (TIMP-1) were measured using ELISA.ResultsPulse wave velocity and serum concentrations of MMP-2 and MMP-9 were higher in HT patients than in the control group. In HT patients PWV was significantly associated (R2 = 0.41) with age (B = 0.408, p = 0.00027), systolic blood pressure (SBP) (B = 0.441, p = 0.0011), and MMP-3 (B = 0.204, p = 0.0459). After 6 months of treatment, regardless of the agent used, we observed a significant decrease of PWV, SBP, MMP-2 and MMP-3 and an increase of TIMP-1 plasma concentration. The decrease of PWV was significantly associated with a decrease of SBP (R2 = 0.07, B = 0.260, p = 0.015) only.ConclusionsIn patients with arterial hypertension, beside age and systolic blood pressure, the determinants of arterial stiffness include serum MMP-3 concentration. For drugs compared in the study with the same hypotensive effect obtained, the arterial stiffness reduction effect is not dependent on the drug used. Systolic blood pressure is one of the independent factors responsible for the reduction of arterial stiffness in the course of antihypertensive treatment.

Hypertension‐induced subclinical vascular and cognitive changes are reversible—An observational cohort study

“…As hypertension is the strongest modifiable risk factor directly leading to arterial stiffness, a number of clinical trials have been carried out in the past to investigate the effect of antihypertensive medications on the change in arterial stiffness. Almost all classes of the tested antihypertensive medications effectively decreased arterial stiffness . In our study group, both stiffness parameters (PWV and AIx) decreased upon antihypertensive treatment; however, the reduction was statistically not significant.…”

Coexistence of proangiogenic potential and increased MMP-9, TIMP-1, and TIMP-2 levels in the plasma of patients with critical limb ischemia

“…These concentrations correlated with clinical signs of instability and plaque rupture in coronary and cerebral vessels. The serum concentrations of MMP-2 and MMP-9 were higher in patients with hypertensive than in the control group (Rajzer et al, 2017). Likewise, the values of plasma MMP-9 were higher in patients with type 2 diabetes mellitus (Vitlianova et al, 2015).…”

The association of endothelin-1 gene polymorphism and its plasma levels with hypertension and coronary atherosclerosis

“…Clinical blood pressure recordings were performed according to the standard technique using a mercury sphygmomanometer [35]. Hypertension was defined as having a systolic blood pressure higher than 140 mm Hg and a diastolic blood pressure more than 90 mm Hg, or having records of taking any kind of anti-hypertension remedy [28,36,37]. Obesity was diagnosed based on the BMI level > 30 kg/m 2 [38].…”